You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Litigation Details for United States v. Holmes (N.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


United States v. Holmes (N.D. Cal. 2018)

Docket ⤷  Try a Trial Date Filed 2018-06-14
Court District Court, N.D. California Date Terminated 2022-12-07
Cause Assigned To Edward John Davila
Jury Demand Referred To Susan G. Van Keulen
Parties ADAM ROSENDORFF; RAMESH "SUNNY" BALWANI; USA
Patents 10,030,059; 10,036,037; 10,046,000; 10,522,245; 6,002,008; 6,005,001; 6,660,267; 7,345,014; 8,008,006; 8,013,002; 8,044,014; 9,000,011; 9,026,372; 9,040,034; 9,056,057; 9,056,059; 9,399,023; 9,415,050; 9,529,976
Attorneys Amanda Mariam McDowell; Benjamin J. Byer; Jeffrey Benjamin Schenk; Jeffrey Bruce Coopersmith; John Curtis Bostic; Joshua Thomas Ferrentino; Kelly Michelle Gorton; Mark Nelson Bartlett; Max Bamberger Hensley; Robert S. Leach; Stephen Anthony Cazares; Steven Fogg
Firms Corr Cronin LLP; Davis Wright and Tremaine; Davis Wright Tremaine LLP; Quinn Emanuel Urquhart & Sullivan, LLP; United States Attorney's Office; United States Attorney's Office, Northern District of California; US Attorney's Office, Northern District of California
Link to Docket External link to docket
Small Molecule Drugs cited in United States v. Holmes
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .
Biologic Drugs cited in United States v. Holmes

Details for United States v. Holmes (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2021-09-07 1002 Exhibit List USP 10,522,245 HOLMES005214 HOLMES005301… Perkins Coie Presentation: Theranos, Inc. Patent Portfolio PC0000048 … D. Taylor Email to A. Shah et al. re Theranos Patent List (with FIG00000703 FIG00000778…"Boies Schiller & Flexner Adds Two Top Patent Litigators" HOLMES002431 HOLMES002433 External link to document
2022-01-18 1271 Transcript AND THEN REMOVING TWO OF THEM AND AVERAGING THE 10:30:59 16 REST? 10:31:00 17 A. YES. …DURING CROSS-EXAMINATION ABOUT 10:30:05 23 PATENTS HELD BY THERANOS? 10:30:07 24 A. YES.…08 25 Q. YOU SAID THAT THERANOS'S PATENTS, WHEN YOU WERE DECIDING …, AND JUST RELIED ON THOSE 10:30:27 6 PATENTS AS EVIDENCE THAT THE TESTS WERE ACCURATE? 10:30… DOES THE FACT THAT A BLOOD TESTING METHOD IS PATENTED MEAN 10:30:36 9 THAT IT'S ACCURATE External link to document
2022-05-31 1469 Order WOULD BE, IF WE'RE ABLE TO, WE WOULD BEGIN AT 9:00 11:07AM 6 AND THEN END AT 3:00 TOMORROW. … 01:26PM 4 PATENTS? 01:26PM 5 A. AGAIN, I'M NOT A PATENT ATTORNEY. I CAN…25PM 19 Q. DID YOU ALSO LOOK AT THE PATENTS THAT THERANOS HAD 01:25PM 20 OBTAINED?… SOME WORK TO TRY TO UNDERSTAND THE BREADTH OF PATENTS. 01:25PM 23 Q. OKAY. AND DO YOU …01:25PM 25 A. AGAIN, I'M NOT A PATENT ATTORNEY EITHER. MY RECOLLECTION External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.